KUREHA (4023) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Despite a decline in revenue, the current period delivered a substantial increase in profits, with margin improvement being the central feature of performance. Revenue declined to ¥1,177.6B (△3.5% YoY), while Operating Income increased significantly to ¥133.4B (+27.5% YoY) and Net Income attributable to owners of the parent rose to ¥103.5B (+27.0% YoY). The increase in profits despite lower revenue was primarily attributable to expanded profit margins resulting from improvements in the cost of sales ratio and the SG&A expense ratio. Cumulative progress against the full-year company plan is high, with Operating Income at 95.3% and Net Income at 102.3%.

Factors Affecting Performance

【Revenue】Revenue was ¥1,177.6B, down 3.5% from ¥1,220.1B in the same period of the previous year. Progress against the full-year plan of ¥1,650.0B was 71.4%, slightly below the standard 75% level, indicating that headwinds remain in terms of demand and volume.

【Profit and Loss】The cost of sales ratio was 70.6% (74.7% in the previous year), while the SG&A expense ratio was 19.8% (19.7% in the previous year), making the improvement in the cost ratio the primary driver of margin expansion. Operating Income increased 27.5% to ¥133.4B (Operating Margin: 11.3%; 8.6% in the previous year), while Profit Before Tax was ¥138.7B and Net Income was ¥103.5B (+27.0%). Financial income of ¥10.5B exceeded financial expenses of ¥5.2B, and equity in earnings of affiliates of ¥13.1B also supported profits. In conclusion, the company achieved higher profits despite lower revenue.

Key Financial Indicators

【Profitability】The Operating Margin was 11.3%, an improvement of approximately 2.7pt YoY, while the Net Profit Margin was 8.8%, an improvement of approximately 2.1pt YoY. The expansion of margins despite declining revenue was largely attributable to improvements in the cost structure.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥208.1B, approximately 2.0 times Net Income of ¥103.5B, indicating sound cash backing for earnings. On the other hand, accounts receivable days and inventory turnover days are relatively long, with funds remaining tied up in working capital.【Investment Efficiency】ROE was 5.6%, and capital efficiency remained relatively low compared with the improvement in the Net Profit Margin. Total asset turnover was approximately 0.33x, while property, plant and equipment accounted for 50.5% of total assets; this capital-intensive asset structure is suppressing turnover.【Financial Soundness】The Equity Ratio was 50.7% (down from 60.6% in the previous year), affected by a decrease in net assets from ¥2,111.4B to ¥1,839.7B due to share repurchases. Current assets were ¥1,058.4B versus current liabilities of ¥826.4B, resulting in a current ratio of approximately 128% and ensuring sufficient capacity to meet short-term obligations.

Cash Flow Analysis

Operating Cash Flow was ¥208.1B, down 19.1% YoY, but remained approximately 2.0 times Net Income of ¥103.5B, indicating favorable conversion of earnings into cash. Investing Cash Flow was an outflow of ¥86.4B, including capital expenditures of ¥149.3B, equivalent to 12.7% of revenue, indicating that high levels of investment continue. Free Cash Flow, calculated by deducting capital expenditures from Operating Cash Flow, remained positive at ¥121.7B. Financing Cash Flow was an outflow of ¥92.1B. In addition to dividend payments of ¥63.4B, the company conducted substantial shareholder returns through share repurchases of ¥390.7B, apparently utilizing financing through borrowings to fund these activities. As a result, cash and cash equivalents increased to ¥256.6B from ¥215.0B in the previous year.

Earnings Quality

The increase in current-period profit was primarily driven by the expansion of Operating Income, with limited reliance on extraordinary or one-time gains and losses. Financial income of ¥10.5B exceeded financial expenses of ¥5.2B, and equity in earnings of affiliates of ¥13.1B (approximately 12.8% of Net Income) also contributed to profit formation; however, these items were not large enough to substitute for the growth in Operating Income. Operating Cash Flow of ¥208.1B substantially exceeded Net Income of ¥103.5B, indicating low accruals and favorable earnings quality. However, the absolute levels of working capital—inventory of ¥448.6B and accounts receivable of ¥309.1B—remain substantial, leaving room for improvement in inventory and receivables turnover efficiency. Comprehensive Income was ¥184.1B, exceeding Net Income of ¥103.5B, supported by increases in other comprehensive income, including foreign currency translation adjustments of ¥29.3B.

Earnings Forecasts and Guidance

Cumulative progress against the full-year company plan was 71.4% for revenue (plan: ¥1,650.0B), 95.3% for Operating Income (plan: ¥140.0B), and 102.3% for Net Income (¥103.5B versus the company plan of ¥100.0B). While revenue progress is slightly behind plan, profit progress is broadly in line with or ahead of plan, indicating that full-year margin improvement is progressing at a faster pace than planned. Against the company plan for a +48.5% YoY increase in Operating Income, cumulative actual growth is limited to +27.5%, making the Q4 profit level the key to achieving the full-year plan.

Shareholder Returns

The dividend is ¥109.50 for the interim period and ¥219.00 on a full-year forecast basis. Relative to cumulative Net Income of ¥103.5B, the Payout Ratio based on the full-year dividend forecast may be high; when considering dividends alone, it can be assessed as being within a sustainable range. Meanwhile, share repurchases during the current period reached ¥390.7B, and total shareholder returns, including dividend payments of ¥63.4B, amounted to approximately ¥454.1B. This substantially exceeded Free Cash Flow of ¥121.7B, meaning that, on a Total Return Ratio basis, shareholder returns exceeded the company’s cash-generation capacity during the current period. Continued returns at this level will require careful fund management through the overall capital policy, including the use of borrowings.

Risk Factors

1. Working Capital Accumulation Risk: The absolute amounts of working capital are substantial, with inventory of ¥448.6B and accounts receivable of ¥309.1B, potentially resulting in inventory write-downs, bad debts, and pressure on Operating Cash Flow.

2. Demand and Volume Risk: Revenue declined 3.5% YoY, and the current increase in profits is highly dependent on margin improvement. Continued revenue declines could lead to deterioration in fixed-cost absorption.

3. Funding Burden from Shareholder Returns: Total shareholder returns, including share repurchases of ¥390.7B, substantially exceed Free Cash Flow of ¥121.7B. Continuing returns at this level would increase reliance on cash and borrowing capacity.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The company’s profitability exceeds the industry median and is at a favorable level close to the upper limit of the IQR.

Growth and Capital Efficiency

The revenue growth rate is substantially below the industry median and is positioned near the lower limit of the IQR.

※Source: Company compilation

Key Points from the Financial Results

1. Despite declining revenue, the Operating Margin improved by approximately 2.7pt YoY, and Operating Income increased 27.5%. The primary drivers of the increase in profit were improvements in the cost ratio and the SG&A expense ratio. The sustainability of profitability improvements not accompanied by revenue growth should be monitored in future quarters.

2. Progress against the full-year plan was 71.4% for revenue, compared with 95.3% for Operating Income and 102.3% for Net Income, indicating that profits are ahead of revenue. Q4 revenue trends will determine the full-year outcome.

3. Total shareholder returns, including share repurchases of ¥390.7B, exceeded Free Cash Flow of ¥121.7B, indicating that the current capital policy was implemented on a scale exceeding cash-generation capacity.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥4,155–¥4,382 at ±1% for the cost of equity, and ¥4,250–¥4,275 at ±0.1 for ω.

Notes:

• Because progress of Net Income against the full-year forecast (102%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of plan tend to exceed forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market stock price, a recommendation of any specific investment action, or a prediction or guarantee of future stock prices.)

---

This report is an automatically generated earnings analysis document created by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional.

---End of Report---

---

AI Financial Analysis

Executive Summary

Kureha delivered a strong FY2026 Q3 earnings result, with substantial profit growth despite a 3.5% year-on-year decline in cumulative nine-month revenue. Revenue was ¥117.76bn, while operating income rose 27.5% to ¥13.34bn. Profit attributable to owners increased 26.4% to ¥10.23bn, equivalent to basic EPS of ¥251.90. The operating margin improved to 11.3% from 8.6% in the prior-year period, an expansion of approximately 276bp. Gross margin increased to 29.4% from 28.2%, or approximately 122bp, indicating that lower sales were more than offset by improved cost of sales efficiency and/or sales mix. SG&A expenses declined 2.7% to ¥23.35bn, while the SG&A-to-revenue ratio increased modestly by approximately 16bp to 19.8% because of the revenue decline. Consequently, operating leverage was favorable, with the improvement in gross profit flowing through strongly to operating income. Pre-tax profit rose 25.0% to ¥13.87bn and the effective tax rate was a normal 25.4%. Finance income of ¥1.05bn exceeded finance costs of ¥0.52bn, supporting pre-tax earnings rather than creating a financing drag. Equity-method investment income was ¥1.31bn, equal to roughly 12.8% of profit attributable to owners and therefore a meaningful contributor to earnings. Operating cash flow of ¥20.81bn exceeded net income by 2.03x, supporting the quality of reported profit. Free cash flow was positive at ¥12.17bn after capital expenditures of ¥14.93bn. However, receivable days of 72, inventory days of 148, and a 143-day cash conversion cycle remain material operating-capital risks for a capital-intensive chemical manufacturer. The balance sheet remains adequately capitalized with a 50.7% equity ratio, although sizable treasury-share purchases reduced total equity year on year. Management's full-year operating-income forecast of ¥14.00bn is already 95.3% achieved at Q3, while the net-income forecast of ¥10.00bn has already been exceeded. The full-year revenue forecast of ¥165.00bn implies a more modest 71.4% Q3 progress rate, suggesting a seasonally stronger fourth quarter in sales or a prudent revenue target. The key issue into Q4 is whether the company can sustain its markedly improved profitability while converting high inventory and receivable balances into cash.

Profitability Analysis

The reported annualized DuPont ROE is 7.4%, comprising an 8.7% net profit margin, 0.437x annualized asset turnover, and 1.95x financial leverage. Margin is the principal positive contributor to the current return profile: the operating margin expanded by approximately 276bp year on year to 11.3%, while the gross margin increased by approximately 122bp to 29.4%. This indicates that gross-profit resilience, rather than top-line expansion, drove the 27.5% increase in operating income. The SG&A ratio rose slightly to 19.8% from 19.7%, so the profit recovery was not driven by material fixed-cost absorption; rather, it reflects a significantly improved gross-profit spread. The annualized asset turnover of 0.437x remains moderate, consistent with the company's PPE intensity of 50.5% of total assets and the working-capital burden associated with chemical manufacturing. Financial leverage of 1.95x supports ROE but does not appear excessive relative to the reported 0.95x debt-to-equity ratio. The tax burden of 0.738 is normal, corresponding to a 25.4% effective tax rate. The interest burden of 1.040 reflects net finance income, with finance income exceeding finance costs by ¥0.53bn. Annualized ROA is approximately 3.9%, calculated using annualized nine-month net income and average total assets, which remains below the 5% benchmark despite the earnings recovery. Thus, Kureha's profitability has strengthened substantially, but return efficiency remains constrained by its asset base and inventory intensity. The sustainability of the higher margin will depend on continued input-cost control, pricing discipline, product mix, and inventory normalization.

Growth Assessment

Nine-month revenue declined 3.5% year on year to ¥117.76bn, demonstrating that current earnings growth is margin-led rather than volume-led. Gross profit nevertheless increased 0.7% to ¥34.66bn as cost of sales declined 5.1%, faster than revenue. Operating income growth of 27.5% therefore materially outpaced sales performance. The company has achieved 71.4% of its full-year revenue forecast at Q3, compared with a standard 75% progress rate, a 3.6 percentage-point shortfall that implies a stronger Q4 sales contribution is required. In contrast, operating income has reached 95.3% of the ¥14.00bn full-year forecast, 20.3 percentage points ahead of the standard Q3 progress rate. Profit attributable to owners has reached 102.3% of the ¥10.00bn forecast, already exceeding the annual target. The large disparity between revenue progress and profit progress indicates that the outlook is highly dependent on maintaining the improved margin structure rather than merely delivering sales growth. Equity-method investment income of ¥1.31bn also supports the earnings outcome, although earnings from investees can fluctuate independently of the consolidated operating business. Other income of ¥1.06bn and other expenses of ¥0.33bn produced a net ¥0.73bn contribution, which is positive but not large enough to be the primary explanation for operating-profit growth. For a chemical manufacturer, revenue durability remains sensitive to customer demand, market pricing, raw-material and energy costs, and the pace at which inventory is worked down.

Financial Health

Financial health is adequate, supported by total equity of ¥183.97bn and a 50.7% equity ratio. Total liabilities were ¥175.25bn, equal to 48.8% of total assets. Current assets of ¥105.84bn exceeded estimated current liabilities of ¥82.64bn, producing a current ratio of approximately 1.28x. This is above the 1.0x warning threshold, so there is no immediate liquidity warning, but it remains below the 1.5x healthy benchmark. Cash and cash equivalents were ¥25.66bn. Current borrowings were ¥41.89bn, exceeding cash by ¥16.23bn, which makes ongoing operating-cash-flow generation and access to debt markets important for refinancing flexibility. Non-current borrowings were ¥76.16bn, leaving the maturity profile weighted toward long-term funding. The reported debt-to-equity ratio of 0.95x is below the 2.0x aggressive-financing threshold. Finance costs of ¥0.52bn were comfortably covered by operating income of ¥13.34bn, while finance income exceeded finance costs. Treasury stock increased in absolute value from ¥15.84bn to ¥37.34bn, a 135.7% year-on-year increase in the negative treasury-stock balance. This was principally caused by ¥39.06bn of treasury-share purchases and reduced equity attributable to owners to ¥182.15bn from ¥209.37bn in the prior-year period. The buyback is a deliberate capital-allocation action but reduces the balance-sheet cushion available for cyclical volatility, large capital projects, or adverse working-capital movements. Other financial assets of ¥26.22bn and investments in equity-method investees of ¥17.64bn provide additional non-operating asset support.

Notable B/S Changes

Treasury stock: increased from -¥15.84bn to -¥37.34bn, a ¥21.49bn change and 135.7% expansion in the negative balance - reflects ¥39.06bn of treasury-share purchases; this materially reduced equity and raises the importance of sustaining cash generation. Total equity: declined by ¥27.17bn year on year to ¥183.97bn - shareholder distributions, especially buybacks, outweighed the contribution from period profit and comprehensive income. Current borrowings: increased from ¥17.77bn to ¥41.89bn, up ¥24.12bn or 135.7% - short-term funding increased materially and should be monitored against cash of ¥25.66bn and current operating-cash-flow generation. Long-term borrowings: increased from ¥62.76bn to ¥76.16bn, up ¥13.40bn or 21.3% - the company maintains a meaningful long-term debt base to fund its capital-intensive operations and capital allocation.

Cash Flow Quality

Cash-flow quality was strong in FY2026 Q3. Operating cash flow was ¥20.81bn, equal to 2.03x net income of ¥10.23bn, well above the 0.8x quality-warning threshold. The accruals ratio was negative 2.9%, which is consistent with favorable cash conversion rather than earnings being dependent on non-cash accruals. Operating cash flow included a ¥2.66bn cash inflow associated with inventories and a ¥1.03bn cash inflow associated with receivables. These movements supported cash generation, while payables produced a modest ¥0.13bn cash outflow. After ¥14.93bn of capital expenditures, free cash flow was ¥12.17bn and remained positive. Capital expenditure represented approximately 12.7% of nine-month revenue, above the typical 3-8% manufacturing range, confirming an investment-intensive operating model. The principal caution is that the favorable working-capital cash contribution occurred despite elevated working-capital duration metrics. DSO of 72 days exceeds the 60-day warning threshold; the root cause is a relatively long customer-collection cycle versus the revenue base. For a chemical manufacturer, extended receivable days may reflect customer terms and sales mix, but the impact is increased credit exposure and a larger cash requirement if collections slow further. DIO of 148 days exceeds both the 90-day general warning level and the 60-day manufacturing efficiency benchmark; the root cause is a large inventory balance of ¥44.86bn, equal to 12.5% of total assets. This may be partly consistent with production planning and supply assurance in specialty chemicals, but its impact is heightened obsolescence, price-decline, and demand-miscalculation risk. The 143-day cash conversion cycle exceeds the 120-day warning threshold, primarily because inventory and receivable days are high relative to supplier financing. Its impact is that future cash conversion can weaken rapidly if inventory stops declining or receivables collection decelerates. Accordingly, strong reported OCF should be viewed as high-quality for the current period, while inventory and collection discipline remain essential to sustain it.

Dividend Sustainability

The Q2 dividend was ¥109.50 per share. The calculated nine-month dividend payout ratio was 53.4%, below the 60% sustainability benchmark and supported by FCF coverage of 2.23x. Cash dividends paid were ¥6.34bn, compared with nine-month free cash flow of ¥12.17bn, indicating that ordinary dividends were covered by internally generated cash. The full-year dividend forecast is ¥219.00 per share, while forecast EPS is ¥249.82, implying an estimated full-year dividend payout ratio of approximately 87.7%. This prospective payout ratio is materially higher than the nine-month calculated ratio and leaves less flexibility if earnings normalize after the current margin recovery. Capital allocation was materially enlarged by ¥39.07bn of share repurchases. Dividends plus buybacks totaled approximately ¥45.41bn, equivalent to roughly 4.4x nine-month profit attributable to owners and approximately 3.7x nine-month FCF. This total return ratio is therefore not covered by current-period free cash flow and was supported by financing inflows and balance-sheet resources. The dividend itself appears cash-flow supportable at the current level, but the combined shareholder-return pace is substantially more demanding and has contributed to the reduction in equity.

Risk Assessment

Business risks include Chemical-market demand, product pricing, raw-material costs, and energy costs can materially affect margins; the current profit recovery occurred despite lower revenue, making preservation of the gross-margin gain central to earnings resilience., Inventory risk is high: DIO of 148 days exceeds both 90-day and 60-day warning thresholds. A demand slowdown, price decline, or product-mix change could require inventory markdowns or lead to weaker operating cash flow., Collection-cycle risk is elevated: DSO of 72 days exceeds the 60-day warning threshold. Slower customer payments would raise credit risk and reverse the current receivables-related operating-cash-flow benefit., The 143-day cash conversion cycle is above the 120-day warning threshold. This indicates a structurally cash-intensive operating cycle and makes cash generation more sensitive to working-capital management., Equity-method investment income of ¥1.31bn is meaningful relative to profit attributable to owners; changes in affiliate performance can add volatility outside consolidated operating profit..

Financial risks include Current borrowings of ¥41.89bn exceed cash and cash equivalents of ¥25.66bn. Although current assets cover current liabilities, refinancing and operating cash generation remain important., Treasury-share purchases of ¥39.06bn exceeded nine-month FCF of ¥12.17bn, reducing equity and increasing reliance on funding capacity for the broader shareholder-return program., The full-year implied dividend payout ratio of approximately 87.7% is high relative to forecast EPS, reducing dividend flexibility if earnings or cash conversion weaken., The reported debt-to-equity ratio of 0.95x is manageable, but continued buybacks can mechanically increase leverage by reducing equity..

Key concerns include Highest priority: inventory normalization and avoidance of inventory impairment or margin pressure, given 148 inventory days and the chemical industry's exposure to cyclical demand and input-price volatility., High priority: sustaining the Q3 operating margin of 11.3% as revenue remains below the prior-year level and full-year sales progress is slightly below the seasonal 75% benchmark., High priority: the cash conversion cycle, because OCF quality is currently strong but depends in part on favorable inventory and receivable cash movements., Moderate priority: capital-allocation discipline following the large buyback, particularly because combined dividends and repurchases substantially exceeded period FCF..

Investment Implications

Key takeaways include Operating profit increased 27.5% to ¥13.34bn despite a 3.5% revenue decline, driven by a 276bp operating-margin expansion to 11.3%., Nine-month net income has already exceeded the ¥10.00bn full-year forecast, while operating income is 95.3% of the full-year target., OCF of ¥20.81bn and FCF of ¥12.17bn provide strong current-period earnings support, with OCF/NI at 2.03x., The central operating constraint is working-capital efficiency: DSO is 72 days, DIO is 148 days, and the cash conversion cycle is 143 days., The ¥39.07bn buyback is much larger than nine-month FCF and has materially reduced equity through the expansion of treasury stock..

Metrics to watch include Revenue recovery and the ability to maintain an operating margin near 11.3% in Q4, Inventory balance and DIO, currently ¥44.86bn and 148 days, Receivable collections and DSO, currently ¥30.91bn and 72 days, Cash conversion cycle, currently 143 days, Full-year operating-income delivery versus the ¥14.00bn forecast, Operating cash flow and FCF after elevated ¥14.93bn nine-month capital expenditure, Further share-repurchase activity, treasury-stock balance, and the resulting equity ratio, Equity-method investment income contribution.

Regarding relative positioning, Kureha's 11.3% operating margin and 8.7% net margin place profitability within the good benchmark range, while annualized ROE of 7.4% remains below the 8% return benchmark. Cash earnings quality is strong, but working-capital efficiency is weak for a manufacturer, with inventory days and the cash conversion cycle well above standard thresholds. The balance sheet is adequately capitalized, although aggressive buybacks have reduced equity and make future capital allocation more consequential.